Real-life costs of hepatitis C treatment

Netherlands Journal of Medicine

Volumn 70, Issue 3, 2012, Pages 145-153

  Helsper, C W ^a   Hellinga, H L ^a   van Essen, G A ^a   de Wit, G A ^b   Bonten, M J M ^a   van Erpecum, K J ^c   Hoepelman, A I M ^a   Richter, C ^d   de Wit, N J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Departments of Gastroenterology   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Costs; Hepatitis C; Treatment

Indexed keywords

PEGINTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEUTROPENIA; RELAPSE; RETROSPECTIVE STUDY; SUSTAINED VIRAL RESPONSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; NETHERLANDS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860205146     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hepatitis C: Global prevalence. Wkly Epidemiol Rec 1997;72:341-344.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558-567.
3. Health Council of the Netherlands: Committee on hepatitis C. Detection and treatment of people with hepatitis C. Rijswijk; 1997. Report No.: 1997/19.
4. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, et al. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med. 2008;66:13-17.
5. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
6. World Health Organization (WHO). State of the art of vaccine research and development. Report number WHO/IVB/05.XX. Available from http://www.who.int/vaccine_research/documents/Viral_Cancers.pdf; 2011.
7. Helsper CW, Borkent-Raven BA, de Wit NJ, et al. Cost-effectiveness of targeted screening for hepatitis C in the Netherlands. Epidemiol Infect. 2011;16:1-12.
8. Zuure FR, Davidovich U, Coutinho RA, et al. Using mass media and the Internet as tools to diagnose hepatitis C infections in the general population. Am J Prev Med. 2011;40:345-352.
9. de Vries MJ, te Rijdt B, van Nieuwkerk CM. Transmission of hepatitis C genotypes in the Netherlands amongst recently genotyped patients. Neth J Med. 2008;66:40-41.
10. de Vries MJ, te Rijdt B, van Nieuwkerk CM. Genotype distribution amongst hepatitis C patients in the Netherlands. Neth J Med. 2006;64:109-113.
11. Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment--fnding the right path. Nat Rev Drug Discov. 2007;6:991-1000.
12. de Bruijne J, Buster EH, Gelderblom HC, et al. Treatment of chronic hepatitis C virus infection - Dutch national guidelines. Neth J Med. 2008;66:311-322.
13. Slavenburg S, Lamers MH, Roomer R, et al. Current clinical care compared with new Dutch guidelines for hepatitis C treatment. Neth J Med. 2009;67:177-181.
14. Oostenbrink JB, Bouwmans C.A.M., Koopmanschap MA, Rutten FF, Jager J, Institute for medical technology assessment EM. Standardisation of costs: The Dutch Manual for Costing in economic evaluations. [in Dutch; Handleiding voor kostenonderzoek: methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg] - Update 2004.
15. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007;20 Suppl 1:S3-S14.
16. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001 Oct 8;161:2231-2237.
17. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat. 2010 Jan;17:34-50.
18. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
19. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.
20. Gevers TJ, Slavenburg S, van Oijen MG, Drenth JP. Treatment extension benefts HCV genotype 1 patients without rapid virological response: a systematic review. Neth J Med. 2011;69:216-221.